Venture • Life Science

HBM Partners Invests In ObsEva

On October 12, 2016, private equity firm HBM Partners invested in life science company ObsEva

Investment Context
  • This is HBM Partners’ 10th transaction in the Life Science sector.
  • This is HBM Partners’ 2nd transaction in Switzerland.
Investment Fate
  • ObsEva went public in 2017.

Explore All 557 Venture Life Science Deals - Search the Database Free


Investment Summary

Date October 12, 2016
Target ObsEva
Sector Life Science
Investor(s) HBM Partners
Deal Type Venture

Target Company

ObsEva

Geneva, Switzerland
ObsEva is a biopharmaceutical company developing novel therapeutics in women's health for the treatment of symptoms associated with endometriosis and uterine fibroids. ObsEva was founded in 2012 and is headquartered in Geneva, Switzerland.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Investor Overview 1

Investor

HBM Partners

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.


Deal Context for Investor #
Overall 12 of 66
Sector: Life Science 10 of 56
Type: Venture 7 of 52
Country: Switzerland 2 of 5
Year: 2016 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-10 Aptinyx

Evanston, Illinois, United States

Aptinyx is a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx was founded in 2015 and is based in Evanston, Illinois.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-01 Swixx Biopharma

Baar, Switzerland

Swixx BioPharma is a specialized distributor of rare diseases, Rx and OTC medicinal products in Central & Eastern Europe, and acts as a true commercialization partner for Biotech & Pharma companies in this area. Swixx Biopharma was founded in 2014 and is based in Baar, Switzerland.

Buy -

Explore Related M&A Activity